v3.25.3

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 20,611	$ 26,301
Marketable securities	4,992	26,774
Prepaid expenses and other current assets	3,221	2,865
Total current assets	28,824	55,940
Long-term equity investments	20,908	20,974
Restricted cash	1,931	1,931
Right-of-use asset, net	11,916	12,797
Property and equipment, net	269	433
Other noncurrent assets	0	92
Total assets	63,848	92,167
Current liabilities:
Accounts payable	1,710	3,192
Accrued expenses	2,959	5,994
Current portion, lease liability	1,409	1,336
Deferred revenue	718	0
Total current liabilities	6,796	10,522
Long-term liabilities:
Lease liability	12,354	13,419
Total liabilities	19,150	23,941
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 1,250 shares issued and outstanding at September 30, 2025 and December 31, 2024	0	0
Common stock, $0.001 par value; 125,000,000 shares authorized; 71,151,981 and 71,009,866 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively	71	71
Additional paid-in-capital	376,129	372,489
Accumulated other comprehensive loss	(126)	(35)
Accumulated deficit	(331,376)	(304,299)
Total stockholders’ equity	44,698	68,226
Total liabilities and stockholders’ equity	$ 63,848	$ 92,167

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Ovid Therapeutics Inc. 10-Q